Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 3/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.37 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.37 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8889178 | 0.90 | ADORA2A (0.41) | DGAT1ADORA2AADORA2BNPC1 | |
| SCHEMBL24752570 | 0.86 | DGAT1 (0.39) | DGAT1F2RL1NPC1 | |
| SCHEMBL14561774 | 0.84 | ADORA2A (0.36) | ADORA2AADORA2B | |
| SCHEMBL31104464 | 0.81 | DGAT1 (0.36) | DGAT1 | |
| SCHEMBL11976878 | 0.80 | DGAT1 (0.43) | DGAT1ADORA2AADORA2BNPC1 | |
| SCHEMBL4312796 | 0.80 | DGAT1 (0.43) | DGAT1ADORA2AADORA2BNPC1 | |
| SCHEMBL8226452 | 0.78 | OPRL1 (0.36) | DGAT1 | |
| SCHEMBL14493341 | 0.76 | ADORA2A (0.37) | DGAT1ADORA2AADORA2BNPC1 | |
| SCHEMBL31104178 | 0.76 | DGAT1 (0.43) | DGAT1F2RL1 | |
| SCHEMBL23533512 | 0.75 | DGAT1 (0.34) | DGAT1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7465740-B2 | 2-heteroaryl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | SCHERING CORPORATION (US) | 2008-12-16 | — | — | US | disclosed |
| US-20070066620-A1 | 2-Heteroaryl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | MERCK SHARP & DOHME LLC | 2007-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066620-A1 | 2-Heteroaryl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | ADORA2A, ADORA3, ADORA1 | DGAT1 3934/4885ADORA2A 1/4885ADORA2B 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.